Immix Biopharma (Nasdaq: IMMX)

Immix Biopharma (Nasdaq: IMMX), a clinical-stage biopharmaceutical innovator, is pioneering the development of cell therapies targeting AL Amyloidosis and other autoimmune disorders. Their flagship product, the CAR-T cell therapy NXC-201, holds FDA IND clearance and is currently under evaluation in the Phase 1b/2 NEXICART-1 clinical trial that commenced in 2021.

Positioned as a potential breakthrough, NXC-201 promises to be the world's first "Single-Day CRS" CAR-T, with a median onset and duration of one day, potentially facilitating quicker patient recoveries and broader applications in autoimmune diseases. The therapy has been recognized with Orphan Drug Designations from both the FDA and the European Commission, underscoring its potential impact.

Founded in 2012 and headquartered in the United States, Immix Biopharma recently secured $15.00 million in Post-IPO Equity investment as of February 2024, signaling investor confidence in its innovative approach within the biotechnology sector.